Wall Street analysts expect ChemoCentryx, Inc. (NASDAQ:CCXI – Get Rating) to report sales of $14.09 million for the current fiscal quarter, according to Zacks Investment Research. Six analysts made ChemoCentryx earnings estimates. The lowest sales estimate is $7.77 million and the highest is $23.78 million. ChemoCentryx recorded sales of $1.81 million in the same quarter last year, indicating a positive year-over-year growth rate of 678.5%. The company is expected to announce its next earnings report on Monday, January 1.
According to Zacks, analysts expect ChemoCentryx to post annual revenue of $88.56 million for the current fiscal year, with estimates ranging from $38.96 million to $153.49 million. dollars. For the next fiscal year, analysts expect the company to post sales of $220.90 million, with estimates ranging from $78.86 million to $580.52 million. Zacks Investment Research averages of sales are an average based on a survey of sell-side analysts who provide coverage for ChemoCentryx.
ChemoCentryx (NASDAQ:CCXI – Get Rating) last released its quarterly earnings data on Thursday, May 5. The biopharmaceutical company reported ($0.55) earnings per share for the quarter, missing the consensus estimate of ($0.31) by ($0.24). ChemoCentryx had a negative net margin of 408.87% and a negative return on equity of 40.75%. During the same period of the previous year, the company posted ($0.43) EPS.
CCXI has been the subject of a number of recent analyst reports. Stifel Nicolaus reworded a “buy” rating and posted a $85.00 price target on ChemoCentryx shares in a research report on Friday, March 18. StockNews.com took over ChemoCentryx stock coverage in a Thursday, March 31 research report. They issued a “sell” rating for the company. One equity research analyst rated the stock with a sell rating, one issued a hold rating, five assigned a buy rating and one assigned a strong buy rating to the company’s stock. Based on data from MarketBeat.com, ChemoCentryx currently has an average rating of “Buy” and a consensus price target of $73.43.
A number of institutional investors and hedge funds have been buying and selling shares of CCXI recently. Zurcher Kantonalbank Zurich Cantonalbank increased its stake in ChemoCentryx shares by 64.4% during the fourth quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 9,534 shares of the biopharmaceutical company valued at $347,000 after purchasing an additional 3,734 shares during the period. Mutual of America Capital Management LLC increased its stake in ChemoCentryx stock by 18.6% in Q4. Mutual of America Capital Management LLC now owns 141,600 shares of the biopharmaceutical company worth $5,156,000 after acquiring an additional 22,200 shares during the period. Strs Ohio increased its stake in ChemoCentryx by 8.0% during the fourth quarter. Strs Ohio now owns 13,500 shares of the biopharmaceutical company valued at $491,000 after buying an additional 1,000 shares in the last quarter. Wasatch Advisors Inc. acquired a new stake in shares of ChemoCentryx during the third quarter valued at approximately $44,033,000. Finally, Keudell Morrison Wealth Management acquired a new position in ChemoCentryx in Q4 valued at approximately $262,000. Institutional investors hold 82.28% of the company’s shares.
Shares of the NASDAQ CCXI opened at $17.38 on Friday. The company has a debt ratio of 0.02, a current ratio of 4.27 and a quick ratio of 4.26. ChemoCentryx has a 1-year low of $9.53 and a 1-year high of $42.16. The company has a market capitalization of $1.21 billion, a price-earnings ratio of -8.65 and a beta of 1.96. The stock’s fifty-day moving average price is $22.63 and its two-hundred-day moving average price is $29.90.
ChemoCentryx Company Profile (Get a rating)
ChemoCentryx, Inc, a biopharmaceutical company, is focused on the development and commercialization of novel drugs for inflammatory disorders, autoimmune diseases and cancer in the United States. It offers TAVNEOS (avacopan), a selective orally administered C5aR inhibitor for the treatment of adult patients with severe active vasculitis associated with neutrophil cytoplasmic autoantibodies.
Get a Free Copy of Zacks Research Report on ChemoCentryx (CCXI)
For more information on Zacks Investment Research’s research offerings, visit Zacks.com
Get news and reviews for ChemoCentryx Daily – Enter your email address below to receive a concise daily summary of the latest news and analyst ratings for ChemoCentryx and related companies with MarketBeat.com’s FREE daily email newsletter.